MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Merck & Co Inc.

Atidarymo kaina

SektoriusSveikatos priežiūra

80.86 3.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.05

Max

82.45

Pagrindiniai rodikliai

By Trading Economics

Pajamos

583M

3.7B

Pardavimai

-1B

16B

P/E

Sektoriaus vid.

11.55

57.333

Pelnas, tenkantis vienai akcijai

1.72

Dividendų pajamingumas

4.15

Pelno marža

23.963

Darbuotojai

73,000

EBITDA

1.3B

6.9B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.27% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.15%

2.63%

Kitas dividendų mokėjimo data

2025-07-07

Kita Ex Dividend data

2025-06-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-56B

196B

Ankstesnė atidarymo kaina

77.35

Ankstesnė uždarymo kaina

80.86

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Merck & Co Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-09 18:18; UTC

Pagrindinės rinkos jėgos

Pharma Shares Reverse Losses After Tariff Pause

2025-04-09 09:39; UTC

Pagrindinės rinkos jėgos

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025-02-04 12:33; UTC

Uždarbis

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

2025-02-04 11:57; UTC

Uždarbis

Merck 4Q Sales Increase Results in Swing to Profit

2025-04-24 20:08; UTC

Uždarbis

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

2025-04-24 16:05; UTC

Svarbiausios naujienos
Uždarbis

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

2025-04-24 14:36; UTC

Rinkos pokalbiai
Uždarbis

Merck's Challenges with Gardasil in China Continue -- Market Talk

2025-04-24 14:10; UTC

Rinkos pokalbiai
Uždarbis

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

2025-04-24 11:35; UTC

Uždarbis

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

2025-04-24 10:58; UTC

Svarbiausios naujienos
Uždarbis

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

2025-04-24 10:55; UTC

Uždarbis

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

2025-04-24 10:31; UTC

Uždarbis

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Keytruda Sales $7.21B >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Pharmaceutical Sales $13.64B >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Keytruda Sales Up 4% >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Pharmaceutical Sales Down 3% >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

2025-04-24 10:30; UTC

Uždarbis

Merck 1Q Januvia/Janumet Sales $796M >MRK

2025-04-24 09:13; UTC

Karštos akcijos

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

2025-03-24 05:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

2025-03-05 19:42; UTC

Svarbiausios naujienos

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

2025-03-05 10:30; UTC

Svarbiausios naujienos

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

2025-02-05 12:00; UTC

Svarbiausios naujienos

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025-02-04 14:48; UTC

Uždarbis

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

2025-02-04 11:51; UTC

Uždarbis

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

2025-02-04 11:50; UTC

Uždarbis

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Akcijų palyginimas

Kainos pokytis

Merck & Co Inc. Prognozė

Kainos tikslas

By TipRanks

35.27% į viršų

12 mėnesių prognozė

Vidutinis 108 USD  35.27%

Aukščiausias 138 USD

Žemiausias 85 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Merck & Co Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

11

Pirkti

7

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

77.85 / 80.02Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.